Lyme disease vaccine - Baxter Healthcare

Drug Profile

Lyme disease vaccine - Baxter Healthcare

Alternative Names: mv rOspA LB vaccine

Latest Information Update: 15 Sep 2015

Price : $50

At a glance

  • Originator State University of New York
  • Developer Baxter Healthcare Corporation
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Lyme disease

Most Recent Events

  • 15 Sep 2015 No recent reports on development identified - Phase-I/II for Lyme disease (Prevention, In volunteers) in Austria and Germany (IM)
  • 06 Aug 2014 Lyme disease vaccine - Baxter Healthcare Corporation is available for licensing or divestiture as of 30 July 2014.
  • 01 Feb 2014 Baxter Healthcare Corporation completes a phase I/II trial in Lyme disease (in volunteers, prevention) in Austria and Germany (NCT01504347)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top